Lupin on Friday said it has received approval from the US Food and Drug Administration for its generic Zileuton extended-release tablets used as prophylaxis and in treatment of chronic asthma in adults and children 12 years of age and older. Citing IQVIA MAT September 2019 data, the company said Zileuton extended-release tablets (600 mg) had annual sales of approximately $43 million in the US. Shareholders will closely monitor product launch and further development.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.